CardiaTec is applying artificial intelligence on large-scale multi-omic data to develop the next generation of cardiovascular disease drug targets. CardiaTec is developing a target discovery platform leveraging AI to make sense of large-scale multi-omic cardiovascular data. As opposed to conventional singular omic analysis, CardiaTec’s proprietary platform unravels relationships that span across every level of biology, from gene variation, methylation, and expression, to their connection to proteomic and metabolomic functions to best understand disease development.

Driven through the newfound understanding of disease biology, CardiaTec is exploring Target-Drug interactions to deliver new treatments to patients faster, cheaper, and with a reduced risk of failure. CardiaTec’s ultimate goal is to help reduce the global burden caused by cardiovascular diseases, which continue as the world's leading global cause of death, claiming over 17 million lives each year.

Through fully integrated multi-omic data aligned with biological modeling, CardiaTec is exploring novel aspects of patient stratification to define patient groups most compatible with our targets & drugs to increase therapeutic outcomes. This serves to facilitate the transition into the next paradigm of personalized medicine for cardiovascular diseases, differentiating from the current one-size-fits-all standards of care.